Zynex Submits 510(k) for NiCO™ CO-Oximeter

Zynex ( (ZYXI) ) has shared an announcement.

On May 12, 2025, Zynex, Inc. announced the submission of a 510(k) application to the FDA for its NiCO™ Noninvasive CO-Oximeter device, marking a significant milestone in pulse oximetry technology. This device addresses the inaccuracies of traditional pulse oximeters, particularly in patients with darker skin, by using laser technology to provide more accurate oxygen and carbon monoxide measurements. This advancement is expected to revolutionize patient monitoring and improve clinical outcomes by providing reliable data for early detection of hypoxia and hyperoxia, thus enhancing patient care and reducing costs.

The most recent analyst rating on (ZYXI) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.

Spark’s Take on ZYXI Stock

According to Spark, TipRanks’ AI Analyst, ZYXI is a Underperform.

Zynex’s stock reflects substantial financial distress and negative momentum. Revenue and profit declines, coupled with high leverage, are critical issues. The earnings call provided some long-term growth opportunities but was overshadowed by current challenges. Technical analysis confirms bearish sentiment, and the lack of dividend yield and negative P/E ratio further weigh down valuation.

To see Spark’s full report on ZYXI stock, click here.

More about Zynex

Zynex, Inc., founded in 1996, is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management, rehabilitation, and patient monitoring, including fluid, sepsis, and laser-based pulse oximetry systems for hospital use.

Average Trading Volume: 307,725

Technical Sentiment Signal: Sell

Current Market Cap: $65.01M

See more insights into ZYXI stock on TipRanks’ Stock Analysis page.